Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ
Status:
Completed
Trial end date:
2021-05-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using
either tamoxifen or anastrozole may fight breast cancer by blocking the use of estrogen. It
is not yet known whether tamoxifen is more effective than anastrozole in preventing breast
cancer after surgery for ductal carcinoma in situ.
PURPOSE: This randomized phase III trial is studying how well adjuvant tamoxifen works
compared to anastrozole in treating postmenopausal women who have undergone surgery to remove
ductal carcinoma in situ.